ReviewCurrent drug discovery technologies2026
Advancements in Drug Discovery Techniques for Cancer Treatment: Clinical Progress and Future Directions.
Review in Current drug discovery technologies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer has emerged as one of the most pressing public health issues in the world and has led to extensive research in novel treatment techniques. Among them, cancer treatment strategies targeting disease-specific pathways have become a focus area. Targeted therapy, based on the premise that tumor cells rely on specific biological pathways, which drugs can block, has dramatically improved therapeutic outcomes with reduced systemic toxicity. Molecule targeted treatment that includes interference with signaling pathway through the small molecule medication, or therapeutic monoclonal antibody, has exceptional anti-cancer effect on most different cancer types that it is primarily prescribed as front-line treatment at this time; and, instead of chemotherapy and conventional therapy treatment, it entails less side-effect risk and the benefit of delivering the killing to cancer cells as it should: namely, far better anti-cancer efficacy. The main problems in conducting molecular targeted therapies include rapid induction of drug-resistant states. For addressing this issue, researchers have taken up many approaches, which include combination therapy, next-generation targeted agents, and adaptive therapy. This review provides a comprehensive overview of the recent advances in targeted therapeutic medications, classifies them, and provides a short description of the target kinases along with mechanisms of action. Clinical examples of targeted therapies are provided and discussed along with potential future research areas. This article also brings to the discussion the need to further investigate mechanisms that would aid in making anti-cancer treatment more efficient, which includes emerging technologies such as nanomedicine, precision oncology, and personalized therapies, making the future bright for cancer care.
Indexed as
Identifiers
40685736What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.